Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
BA-1301 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
BA-1301: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CDR-404 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
CDR-404: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ASKG-915 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
ASKG-915: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
NT-219 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
NT-219: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
NGGT-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
NGGT-001: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
PM-1009 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
PM-1009: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
(S)-Perillyl Alcohol Temozolomide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
(S)-Perillyl Alcohol Temozolomide: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ACI-7104 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
ACI-7104: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Sarcoma vaccine(Memorial Sloan-Kettering Cancer Center) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
Sarcoma vaccine(Memorial Sloan-Kettering Cancer Center): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP.
8 min read
SHJ-002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
SHJ-002: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ODM-203 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
ODM-203: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
PP-405(Pelage Pharmaceuticals) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
PP-405(Pelage Pharmaceuticals): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.